Rankings
▼
Calendar
ABCL Q2 2025 Earnings — AbCellera Biologics Inc. Revenue & Financial Results | Market Cap Arena
ABCL
AbCellera Biologics Inc.
$1B
Q2 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$17M
+133.3% YoY
Gross Profit
$17M
100.0% margin
Operating Income
-$50M
-290.2% margin
Net Income
-$35M
-203.3% margin
EPS (Diluted)
$-0.12
QoQ Revenue Growth
+303.4%
Cash Flow
Operating Cash Flow
-$32M
Free Cash Flow
-$46M
Stock-Based Comp.
$14M
Balance Sheet
Total Assets
$1.4B
Total Liabilities
$395M
Stockholders' Equity
$1.0B
Cash & Equivalents
$92M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$17M
$7M
+133.3%
Gross Profit
$17M
$7M
+133.3%
Operating Income
-$50M
-$93M
+46.9%
Net Income
-$35M
-$37M
+6.0%
Revenue Segments
License
$10M
61%
Research Fees
$7M
39%
← FY 2025
All Quarters
Q3 2025 →